Profound Medical Corp.
Income Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.5M | $5.3M | $6.0M | $5.3M | $2.2M | $2.6M | $4.2M | $2.8M |
| Cost of Revenue | $536.0K | $1.5M | $2.0M | $1.4M | $593.0K | $768.0K | $1.2M | $1.0M |
| Gross Profit | $1.9M | $3.8M | $4.0M | $3.9M | $1.6M | $1.9M | $3.0M | $1.8M |
| Gross Margin | 78.4% | 71.8% | 66.8% | 74.3% | 73.2% | 70.7% | 70.9% | 63.1% |
| Operating Expenses | ||||||||
| Research & Development | $5.7M | $5.3M | $4.3M | $5.4M | $6.1M | $4.8M | $4.6M | $4.2M |
| SG&A Expense | $7.4M | $6.6M | $7.1M | $7.4M | $9.3M | $8.2M | $6.7M | $6.6M |
| Operating Income | $-11.1M | $-8.0M | $-7.4M | $-8.9M | $-13.8M | $-11.2M | $-8.3M | $-9.0M |
| Operating Margin | -445.7% | -150.3% | -123.3% | -168.5% | -624.4% | -426.0% | -199.8% | -317.7% |
| Interest Expense | — | $80.0K | — | — | — | $104.0K | — | — |
| Pretax Income | $-9.5M | $-7.0M | $-8.1M | $-7.9M | $-15.6M | $-10.7M | $-5.2M | $-9.2M |
| Income Tax Expense | $55.0K | $25.0K | $26.0K | $121.0K | $64.0K | $41.0K | $-238.0K | $177.0K |
| Net Income | $-9.5M | $-7.1M | $-8.2M | $-8.0M | $-15.7M | $-10.7M | $-4.9M | $-9.4M |
| Net Margin | -384.2% | -132.2% | -136.8% | -150.8% | -709.9% | -409.2% | -118.5% | -330.7% |
| EPS (Basic) | $-0.26 | $0.19 | $1.31 | $0.26 | $-0.52 | $0.36 | $0.19 | $0.38 |
| EPS (Diluted) | $-0.26 | $0.19 | $1.31 | $0.26 | $-0.52 | $0.36 | $0.19 | $0.38 |
| Shares Outstanding (Basic) | 36.4M | 36.3M | 30.2M | 30.1M | 30.1M | 30.0M | 24.8M | 24.5M |
| Shares Outstanding (Diluted) | 36.4M | 36.3M | 30.2M | 30.1M | 30.1M | 30.0M | 24.8M | 24.5M |
| Dividends Per Share | — | — | — | — | — | — | — | — |